KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance

Pathology Research and Practice

Volumn 210, Issue 5, 2014, Pages 307-311

  Miglio, Umberto ^a   Oldani, Alberto ^a   Mezzapelle, Rosanna ^a,b   Veggiani, Claudia ^c   Paganotti, Alessia ^c   Garavoglia, Marcello ^a   Boldorini, Renzo ^a,c  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Laboratory of Cancer Genomics   (Italy)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Adenocarcinoma; KRAS mutations; Pancreas

Indexed keywords

ASPARTIC ACID; GLYCINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CODON; FEMALE; GENE FREQUENCY; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; POINT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR VOLUME; VERY ELDERLY; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84898056925     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.01.011     Document Type: Article

References (23)

1. Ahlgren J.D. Epidemiology and risk factors in pancreatic cancer. Semin. Oncol. 1996, 23:241-250.
2. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
3. Di Magliano M.P., Longsdon C.D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013, 144:1220-1229.
4. Dillon D.A., Johnson C.C., Topazian M.D., Tallini G., Rimm D.L., Costa J.C. The utility of Ki-ras mutation analysis in the cytologic diagnosis of the pancreatobiliary neoplasma. Cancer J. 2000, 6:294-301.
5. Finkelstein S.D., Przygodzki R., Pericolo V.E., Sayegh R., Bakker A., Swalsky P.A., Keller G. K-ras topographic genotyping of pancreatic adenocarcinoma. Arch. Surg. 1994, 12:9367-9372.
6. Furukawa H., Okada S., Saisho H., Ariyama J., Karasawa E., Nakaizumi A., Nakazawa S., Murakami K., Kakizoe T. Clinicpathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996, 78:986-990.
7. Wagner M., Redaelli C., Lietz M., Seiler C.A., Friess H., Büchler M.W. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br. J. Surg. 2004, 91:586-594.
8. Howe J.R., Conlon K.C. The molecular genetics of pancreatic cancer. Surg. Oncol. 1997, 6:1-18.
9. Hruban R.H., Boffetta P., Hiraoka N., Iacobuzio-Donahue C., Kato Y., Kern S.E., et al. Ductal adenocarcinoma of the pancreas. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System 2010, 279-291. IARC Press, Lyon, France. 4th edition. F.T. Bosman, F. Carnerio, R.H. Hruban, N.D. Theise (Eds.).
10. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 2000, 6:2969-2972.
11. Imamura Y., Morikawa T., Liao X., Lochhead P., Kuchiba A., Yamauchi M., Qian Z.R., Nishihara R., Meyerhardt J.A., Haigis K.M., Fuchs C.S., Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 2012, 18:4753-4763.
12. Immervoll H., Hoem D., Kugarajh K., Steine S.J., Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006, 448:788-796.
13. WAF-1, cyclin D1, ERBB-2 and ERBB-3 in resected pancreatic ductal adenocarcinoma. Int. J. Cancer (Pred. Oncol.) 2000, 89:469-474.
14. Kim J., Reber H.A., Dry S.M., Elashoff D., Chen S.L., Umetani N., Kitago M., Hines O.J., Kazanjian K.K., Hiramatsu S., Bilchik A.J., Yong S., Shoup M., Hoon D.S. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 2006, 55:1598-1605.
15. Knijn N., Mekenkamp L.J.M., Klomp M., Vink-Börger M.E., Tol J., Teerenstra S., Meijer J.W., Tebar M., Riemersma S., van Krieken J.H., Punt C.J., Nagtegaal I.D. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br. J. Cancer 2011, 104:1020-1026.
16. Lee J., Jang K.T., Ki C.S., Lim T., Park Y.S., Lim H.Y., Choi D.W., Kang W.K., Park K., Park J.O. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007, 109:1561-1569.
17. Mezzapelle R., Miglio U., Rena O., Paganotti A., Allegrini S., Antona J., Molinari F., Frattini M., Monga G., Alabiso O., Boldorini R. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br. J. Cancer 2013, 108:1743-1749.
18. Oliveira-Cunha M., Hadfield K.D., Siriwardena A.K., Newman W. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas 2012, 41:428-434.
19. Scarpa A., Capelli P., Villaneuva A., Zamboni G., Lluìs F., Accolla R., Mariuzzi G., Capellà G. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int. J. Cancer 1994, 57:167-171.
20. Schultz N.A., Roslin A., Christensen I.J., Horn T., Høgdall E., Pedersen L.N., Kruhøffer M., Burcharth F., Wøjdemann M., Johansen J.S. Frequency and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 2012, 41:759-766.
21. Slebos R.J.C., Hoppin J.A., Tolbert P.E., Holly E.A., Brock J.W., Zhang R.H., Bracci P.M., Foley J., Stokton P., McGregor L.M., Flake G.P., Taylor J.A. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol. Biomarkers Prev. 2000, 9:1223-1232.
22. Smit V.T., Boot A.J., Smits A.M.M., Fleuren G.J., Cornelisse C.J., Bos J.L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acid Res. 1988, 16:7773-7782.
23. Tan C., Du X. KRAS mutation testing in metastatic colorectal cancer. World J. Gastroenterol. 2012, 18:5171-5180.